1. India Stocks

  2. •

    Distribution services

  3. •

    Medical distributors
Bijoy Hans Ltd.

Bijoy Hans Ltd.

BBSE:BIJHANS
104.05
INR
+4.95
(+4.99%)
0.27EPS
285.24P/E
2.65BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
1.09
1.64
1.42
4.38
1.46
1.33
1.64
1.34
1.09
1
0.93
0.92
1.9
3.26
Basic EPS, GAAP
0.12
0.01
-0.18
-0.43
-0.38
-0.27
-0.18
-0.3
-0.63
-1.48
-0.39
0.45
0.15
0.19
Free Cash Flow per Basic Share
-0.34
0.55
-0.76
-1.76
-0.52
0.08
-0.27
-0.06
-1.23
-1.25
-0.98
-0.09
-1.65
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
15.83
15.84
15.36
14.93
14.55
14.28
14.1
13.8
13.18
11.7
11.31
11.76
12.47
12.47
Tangible Book Value per Share
15.83
15.84
15.36
14.93
14.55
14.28
14.1
13.8
13.18
11.7
11.31
11.76
6.57
6.57
Basic Weighted Avg Shares
3
2
3
3
3
3
3
3
3
3
3
3
48
28
Sales/Revenue/Turnover
3
4
4
13
4
4
5
4
3
3
3
3
91
91
Operating Margin (%)
-68.71
-83.93
-75.2
-26.79
-81.17
-77.1
-57.26
-72.86
-103.32
-127.04
-147.81
-196.51
1.19
-0.58
Depreciation Expense
1
1
1
1
1
1
- -
- -
- -
1
- -
- -
6
6
Net Income, GAAP
- -
- -
-1
-1
-1
-1
-1
-1
-2
-4
-1
1
7
5
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
28.65
17.38
20.38
Profit Margin (%)
10.98
0.61
-12.67
-9.82
-25.87
-20.25
-10.95
-22.02
-57.67
-148.23
-41.88
48.8
7.71
5.94
Working Capital
35
37
36
34
33
34
30
28
28
17
18
29
54
54
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
- -
435
435
Total Equity
48
48
46
45
44
43
42
41
40
35
34
35
631
631
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.21
0.15
-0.07
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
4.06
1.45
1.15
Return on Common Equity (%)
0.76
0.05
-1.15
-2.87
-2.56
-1.86
-1.27
-2.12
-4.65
-11.9
-3.4
3.93
2.21
1.71

Capital Structure

INR

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
- -
- -
59
LT Borrowings
- -
- -
80
LT Finance Leases
- -
- -
354
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
8
48
48
Market Capitalization
295
2,406
2,652

Working Capital

INR

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
34
- -
381
Cash, Cash Equivalents & STI
13
- -
86
Accounts Receivable, Net
- -
- -
22
Inventories
- -
- -
19
Total Current Liabilities
1
- -
327
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
59
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
166.2%
334.51%
1,687.67%
Free Cash Flow
3,098.75%
6,315.62%
29,619.1%
Net Income, GAAP
50.59%
74.87%
416.09%
Sales/Revenue/Turnover
327.5%
626.68%
3,167.59%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1
1
1
1
3
2025
1
1
1
- -
3
2026
- -
- -
- -
91
91

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.02
-0.18
-0.13
-0.07
-0.39
2025
-0.17
-0.47
1.78
-0.68
0.45
2026
-0.34
-0.41
-0.03
0.26
0.15

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Kaushal Uttam Shah
Full Time Employees
- -
Sector
Distribution services
Industry
Medical distributors
Address
Unit No 408 Miraj MA India 416410
IPO Date
Jul 18, 2005
Website
bijoyhans.net
Similar Companies
DataMeds AI, Inc. (NASDAQ:MEDS)
Selcuk Ecza Deposu Ticaret ve Sanayi A.S. (BIST:SELEC)
McKesson Corporation (NYSE:MCK)
Ibnsina Pharma (EGX:ISPH)
Cardinal Health, Inc. (NYSE:CAH)
Entero Healthcare Solutions Limited (NSE:ENTERO)
Business
Bijoy Hans Limited operates as an Indian pharmaceutical company engaged in the manufacturing and wholesale distribution of pharmaceutical formulations and medical goods. The company’s core products include tablets, capsules, syrups, suspensions, and powders, with a focus on key therapeutic segments such as antibiotics, cough/cold/allergy remedies, H-1 receptor antagonists (antiulcerants), nutraceuticals, and non-steroidal anti-inflammatory drugs (NSAIDs). Founded in 1985 and headquartered in Guwahati, Bijoy Hans serves the Indian market through these diversified pharmaceutical product offerings. In the latest strategic developments during 2024 and 2025, Bijoy Hans has significantly expanded its operations through acquisitions and equity capital increases. The company increased its authorized share capital from Rs. 10 crore to Rs. 60 crore to support growth initiatives and approved acquisitions of 100% equity stakes in three healthcare-related companies: Health Secure Hospitals Private Limited, Arvaya Health and Wellness Private Limited, and Tec-Pool Solutions Private Limited, with total purchase considerations approximating Rs. 50 crore. These moves mark a major strategic shift towards healthcare services and wellness, diversifying beyond its pharmaceutical production base. Additionally, the company secured regulatory approvals for preferential allotments of equity shares to promoters, reinforcing promoter stake and capital base. Board and management changes occurred with the appointment of new independent directors and leadership realignments aligned with these expansions. Bijoy Hans operates primarily within the pharmaceutical and medical goods industry in India, focusing on the domestic wholesale and retail pharmaceutical market. Its subsidiaries under the recent acquisitions widen its business scope into hospital services, health and wellness solutions, and technology-enabled healthcare services. The company targets healthcare providers, pharmacies, and end consumers seeking pharmaceutical and allied healthcare products. These developments position Bijoy Hans for enhanced market presence in the pharmaceutical manufacturing sector alongside an expanding footprint in integrated healthcare services. This evolving business profile underscores Bijoy Hans Limited’s strategy to leverage its manufacturing expertise while capitalizing on growing healthcare infrastructure demands in India through vertical integration and diversification efforts in recent years. The company’s comprehensive pharmaceutical product range combined with strategic acquisitions reflects a broadened operational focus and strengthened financial platform aimed at sustainable growth and expanded service offerings in the healthcare sector.